AbbVie (ABBV, 4AB, 0QCV) → Stock, financial statements

AbbVie: stocks, financial statements

Dividends News

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.

  • 0QCV, 4AB, ABBV Ticker
  • NYSE, F, XETRA, LSE Exchange
  • 30,000 Employees
179 rated

Financial statements — AbbVie

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
46B 33B 33B 28B 26B
Cost Of Revenue
15B 7.4B 7.7B 7B 5.8B
Gross Profit
30B 26B 25B 21B 20B
Research and Development
6.6B 6.4B 10B 5B 4.4B
Selling General and Admin
11B 6.9B 7.4B 6.3B 5.9B
Operating Expense
33B 21B 25B 18B 16B
Operating Income
13B 12B 7.3B 9.9B 9.6B
Other Income Expense Net
0 0 0 0 0
13B 12B 7.3B 9.9B 9.6B
Interest Income
2.3B 1.5B 1.1B 1B 970M
Pretax Income
3.4B 8.4B 5.2B 7.7B 7.9B
Income Tax
-1.2B 540M -490M 2.4B 1.9B
Minority Interest
6M 0 0 0 0
Net Income
4.6B 7.8B 5.7B 5.3B 5.9B
Net Income Basic
4.6B 7.8B 5.7B 5.3B 5.9B
20 ← 16 2020 2019 2018 2017 2016
Current cash
8.5B 40B 8.1B 9.8B 6.4B
Short term investments
3.6B 2.4B 1.9B 4.7B 3.6B
8.8B 5.4B 5.4B 5.1B 4.8B
3.3B 1.8B 1.6B 1.6B 1.4B
Other current assets
3.6B 2.4B 1.9B 4.7B 3.6B
Current assets
24B 50B 17B 21B 16B
Long term investments
130B 40B 42B 50B 50B
Property plant equipment
5.2B 3B 2.9B 2.8B 2.6B
33B 16B 16B 16B 15B
Intangible assets
83B 19B 21B 28B 29B
Other assets
4.9B 2.3B 1.2B 1.3B 1.2B
Total assets
150B 89B 59B 71B 66B
Accounts payable
2.3B 1.5B 1.5B 1.5B 1.4B
Current long term debt
8.5B 3.8B 5.3B 6.4B 400M
Other current liabilities
18B 10B 10B 8.8B 8B
Total current liabilities
29B 16B 17B 17B 9.8B
Long term debt
78B 63B 35B 31B 36B
Other liabilities
28B 18B 14B 16B 8.4B
Minority Interest
21M 0 0 0 0
Total Liabilities
140B 97B 68B 66B 61B
Common stock
1.7B 1.5B 1.5B 1.6B 1.6B
Retained earning
1.1B 4.7B 3.4B 5.5B 4.4B
Treasury stock
-2.3B -25B -24B -12B -11B
Capital surplus
Shareholder equity
13B -8.2B -8.4B 5.1B 4.6B
Net tangible assets
-100B -42B -45B -38B -40B
20 ← 16 2020 2019 2018 2017 2016
Net Income
4.6B 7.8B 5.7B 5.3B 5.9B
6.5B 2B 1.8B 1.5B 1.2B
Changes in receivables
3.4B 44M 300M 330M 28M
Changes in inventories
1.5B 210M 0 160M -280M
Cash change
-31B 32B -1.7B 3.4B -2B
Cash flow
18B 13B 13B 10B 7B
Capital expenditures
-800M -550M -640M -530M -480M
Investing activity other
Total investing cash flows
-38B 600M -1B -270M -6.1B
Dividends paid
Net borrowings
74B 24B 30B 23B 27B
Other financing cash flows
Cash flow financing
-12B 19B -14B -5.5B -3.9B
Exchange rate effect